These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22849846)

  • 41. Verification of skin autofluorescence values by mass spectrometry in adolescents with type 1 diabetes: brief report.
    Mácsai E; Takáts Z; Derzbach L; Körner A; Vásárhelyi B
    Diabetes Technol Ther; 2013 Mar; 15(3):269-72. PubMed ID: 23343332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.
    Hartog JW; de Vries AP; Lutgers HL; Meerwaldt R; Huisman RM; van Son WJ; de Jong PE; Smit AJ
    Ann N Y Acad Sci; 2005 Jun; 1043():299-307. PubMed ID: 16037252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advanced glycation end products in the skin are enhanced in COPD.
    Hoonhorst SJ; Lo Tam Loi AT; Hartman JE; Telenga ED; van den Berge M; Koenderman L; Lammers JW; Boezen HM; Postma DS; Ten Hacken NH
    Metabolism; 2014 Sep; 63(9):1149-56. PubMed ID: 25034386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients.
    Canbakan M; Sahin GM
    Ren Fail; 2007; 29(3):289-93. PubMed ID: 17497442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution.
    MacGinley R; Cooney K; Alexander G; Cohen S; Goldsmith DJ
    Am J Kidney Dis; 2002 Nov; 40(5):1030-5. PubMed ID: 12407649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis.
    Touré F; Lavaud S; Mohajer M; Lavaud F; Canivet E; Nguyen P; Chanard J; Rieu P
    Kidney Int; 2004 Feb; 65(2):654-60. PubMed ID: 14717938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe exfoliative skin rash with icodextrin.
    Almiani M; Kohn OF
    Kidney Int; 2014 Aug; 86(2):449. PubMed ID: 25079030
    [No Abstract]   [Full Text] [Related]  

  • 48. Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis.
    Mácsai E; Benke A; Kiss I
    Medicine (Baltimore); 2015 Nov; 94(45):e1933. PubMed ID: 26559261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polyglucose solutions in CAPD.
    Wilkie ME; Brown CB
    Perit Dial Int; 1997; 17 Suppl 2():S47-50. PubMed ID: 9163797
    [No Abstract]   [Full Text] [Related]  

  • 50. [Optimal use of peritoneal dialysis fluids in type 2 diabetes mellitus patients].
    Ryckelynck JP; Allard C; Cousin M; Hurault de Ligny B; El Haggan W; Lobbedez T
    Nephrol Ther; 2006 Jan; 2 Suppl 1():S82-5. PubMed ID: 17378147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical experience with icodextrin. Multicenter study].
    Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Remón C; Fernández-Ruiz EJ; Pérez-Bañasco V; Benítez M; Martínez-Benavides E; Martínez-González JM; Torán D; Tejuca F; Páez C; del Pino MD
    Nefrologia; 2001; 21(6):574-80. PubMed ID: 11881427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sterile icodextrin-associated peritonitis may induce hypersensitivity and recurrent peritonitis on re-challenge.
    Enia G; Mandalari A; Ventura G; Pustorino D; Panuccio V
    Nephrol Dial Transplant; 2003 Mar; 18(3):626. PubMed ID: 12584300
    [No Abstract]   [Full Text] [Related]  

  • 53. Sodium removal and peritoneal dialysis modalities: no differences with optimal prescription of icodextrin.
    Fourtounas C; Dousdampanis P; Hardalias A; Vlachojannis JG
    Artif Organs; 2013 Jul; 37(7):E107-13. PubMed ID: 23461737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.
    Plum J; Gentile S; Verger C; Brunkhorst R; Bahner U; Faller B; Peeters J; Freida P; Struijk DG; Krediet RT; Grabensee B; Tranaeus A; Filho JC
    Am J Kidney Dis; 2002 Apr; 39(4):862-71. PubMed ID: 11920355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Icodextrin cutaneous hypersensitivity: report of 3 psoriasiform cases.
    Valance A; Lebrun-Vignes B; Descamps V; Queffeulou G; Crickx B
    Arch Dermatol; 2001 Mar; 137(3):309-10. PubMed ID: 11255330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients.
    Cho KH; Do JY; Park JW; Yoon KW
    Nephrol Dial Transplant; 2010 Feb; 25(2):593-9. PubMed ID: 19767632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients.
    Amici G; Orrasch M; Da Rin G; Bocci C
    Adv Perit Dial; 2001; 17():80-3. PubMed ID: 11510303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients.
    Kuriyama R; Tranaeus A; Ikegami T
    Adv Perit Dial; 2006; 22():108-10. PubMed ID: 16983951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peritoneal dialysis in patients with diabetes: are the benefits greater than the disadvantages?
    Kuriyama S
    Perit Dial Int; 2007 Jun; 27 Suppl 2():S190-5. PubMed ID: 17556303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute pancreatitis in a 2-year-old girl on peritoneal dialysis and using icodextrin solution.
    Fujinaga S; Nishizaki N; Hirano D; Kanai H; Suzuki M; Ohtomo Y; Kaneko K; Shimizu T
    Clin Nephrol; 2011 Jan; 75(1):89-90. PubMed ID: 21176756
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.